Metastatic Cutaneous Melanoma - Europe PMC

Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina.

Observation Two eyes of two patients with cutaneous melanoma metastatic to the vitreoretina were eye treated with a combination of intravitreous melphalan and bevacizumab administered sequentially during the same office visit at monthly intervals. In addition, treatment reversed neovascular glaucoma and dramatically improved vision in one patient's eye, as well as stabilizing vision without the appearance of neovascularization in the eye of the other patient. Conclusions and importance Combination, continuous intravitreous melphalan and bevacizumab are well tolerated and considered a safe and effective treatment of eye disease with intraocular metastatic melanoma.

Source link: https://europepmc.org/article/MED/35464680

Cutaneous immune-related adverse events and photodamaged skin in metastatic melanoma patients: Could the use of nicotinamide be useful?

In more than one-third of patients treated with immune checkpoint inhibitors, they are usually the first clinical signs, although they may occur months after diagnosis. We discovered that our patients have these cutaneous adverse events on photodamaged skin. Patients with significant cutaneous actinic injury were diagnosed with cutaneous immuno-related adverse reactions earlier and in a more acute manner, in fact out of 19 patients being treated for metastatic melanoma.

Source link: https://europepmc.org/article/MED/35396736

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: a retrospective single center study.

Methods This is a retrospective single center cohort study that includes patients with stage IV or inoperable stage III metastatic melanoma diagnosed with BRAFi+MEKi therapy or immunotherapy with Checkpoint inhibitors. A total of 286 patients with stage III-IV metastatic melanoma were included in the study: 146 received immunotherapy and 140 targeted therapy. In addition, multivariate logistic regression shows a significant correlation between skin adverse events and immunotherapy, as well as between cutaneous AEs and metastatic settings. We also found that as the age of start of therapy increases, the likelihood of experiencing skin toxicity rises. However, stratifying by type of drugs remains true in immunotherapy, though target therapy age does not influence skin toxicity onset, although infant immunotherapy does not influence skin toxicity onset. Patients were also evaluated regardingconcomitant drugs, and it appears that Levotyroxine may also play a role in AEs during immunotherapy therapy.

Source link: https://europepmc.org/article/MED/35384181

Primary vitreoretinal involvement and immunopositivity for BRAFV600E help distinguish metastatic from primary intraocular melanoma: a detailed histopathologic study of metastatic cutaneous melanoma to the eye.

The aim of this study is to assess the morphopathologic characteristics of metastatic cutaneous melanoma to the eye, as well as the more common primary uveal melanoma; specifically, tumour location within the eye, cytomorphology, and immunohistochemical/specific molecular genetic signatures. Methods A retrospective case series was developed using surgical enucleation and diagnostic vitrectomy cytologic samples from seven patients with alleged intraocular melanoma, which was later diagnosed as metastatic melanoma. Patients with metastatic melanoma have primary vitreoretinal involvement and epithelioid, poorly malignant cytomorphology; many have BRAFV600E mutations, a finding not seen in large cohorts of primary uveal melanoma.

Source link: https://europepmc.org/article/MED/35275414

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.

Methods of Analysis The Canadian Melanoma Research Network obtained national data of patients with newly diagnosed BRAF-mutated metastatic melanoma. In the 1L-IO group, there were more patients with ECOG 0-1 than in the 1L-TT group than in the 1L-TT group. However, patients who received 1L-TT then 2L-IO had the longest OS compared to 1L-IO without 2L therapy, 1L-IO then 2L-TT, and 1L-TT without 2L therapy accounted for 1L-TT. Those who received 2L-therapy, patients who received 2L-IO, had a trend toward OS improvement compared to the 2L-TT group.

Source link: https://europepmc.org/article/MED/35323326

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions